Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Invitae Corp (NVTA)
Invitae Corp (NVTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,650
  • Shares Outstanding, K 286,493
  • Annual Sales, $ 516,300 K
  • Annual Income, $ -3,106 M
  • 60-Month Beta 1.65
  • Price/Sales 0.28
  • Price/Cash Flow 0.06
  • Price/Book N/A
Trade NVTA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.11
  • Most Recent Earnings -0.10 on 11/08/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 132.64% ( -16.59%)
  • Historical Volatility 176.10%
  • IV Percentile 73%
  • IV Rank 46.39%
  • IV High 226.22% on 03/28/23
  • IV Low 51.66% on 09/27/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 379
  • Volume Avg (30-Day) 1,019
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 164,450
  • Open Int (30-Day) 166,593

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.27
  • Number of Estimates 7
  • High Estimate -0.23
  • Low Estimate -0.34
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +20.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +60.61%
on 11/09/23
0.7300 -20.79%
on 11/08/23
+0.0024 (+0.42%)
since 11/01/23
3-Month
0.3600 +60.61%
on 11/09/23
0.9791 -40.95%
on 09/05/23
-0.3877 (-40.14%)
since 09/01/23
52-Week
0.3600 +60.61%
on 11/09/23
2.9400 -80.33%
on 01/18/23
-2.3918 (-80.53%)
since 12/01/22

Most Recent Stories

More News
1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

NVDA : 467.65 (-0.01%)
TSLA : 238.83 (-0.52%)
U : 32.52 (+10.20%)
NVTA : 0.5782 (+13.77%)
ARKK : 48.43 (+5.03%)
$NASX : 14,305.03 (+0.55%)
RXRX : 7.39 (+7.88%)
Invitae (NVTA) Q3 2023 Earnings Call Transcript

NVTA earnings call for the period ending September 30, 2023.

NVTA : 0.5782 (+13.77%)
Invitae: Q3 Earnings Snapshot

Invitae: Q3 Earnings Snapshot

NVTA : 0.5782 (+13.77%)
3 Things About Invitae Every Smart Investor Knows

The last two years have been tumultuous, and there are no calm waters in sight.

NVTA : 0.5782 (+13.77%)
Is Invitae Stock a Buy Now?

Invitae shares have dropped more than 60% this year.

NVTA : 0.5782 (+13.77%)
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D.,...

NVTA : 0.5782 (+13.77%)
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal hereditary cancer...

NVTA : 0.5782 (+13.77%)
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

/PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of...

NVTA : 0.5782 (+13.77%)
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers...

NVTA : 0.5782 (+13.77%)
Why Invitae Stock Popped Today

Invitae just received a key marketing authorization from the FDA for a first-of-its-kind cancer test.

NVTA : 0.5782 (+13.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 0.6825
2nd Resistance Point 0.6303
1st Resistance Point 0.6043
Last Price 0.5782
1st Support Level 0.5261
2nd Support Level 0.4739
3rd Support Level 0.4479

See More

52-Week High 2.9400
Fibonacci 61.8% 1.9544
Fibonacci 50% 1.6500
Fibonacci 38.2% 1.3456
Last Price 0.5782
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar